Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Jubilant Life Sciences Limited, once a prominent integrated global pharmaceutical and life sciences company, is now primarily recognised for its transformed entities. Headquartered in Noida, India, as part of the Jubilant Bhartia Group established in 1978, its core pharmaceutical preparation manufacturing businesses now operate under Jubilant Pharmova Limited, with a significant global footprint across North America, Europe, and India.
Jubilant Pharmova, the successor entity, excels in active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, and allergy therapy products. It is also a key global provider of contract manufacturing and development services (CDMO), leveraging extensive capabilities to deliver innovative solutions and contribute substantially to worldwide healthcare.
+7 vs industry average
Jubilant Life Sciences’s score of 49 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Jubilant Life Sciences, a Pharmaceutical Preparation Manufacturing company with its HQ in India, reported its most recent carbon emissions for 2025. The company's Scope 1 emissions were 10,084,000 kg CO2e, Scope 2 emissions were 64,219,000 kg CO2e, and Scope 3 emissions were 527,407,000 kg CO2e. For the previous year, 2024, the company reported Scope 1 emissions of 8,620,000 kg CO2e, Scope 2 emissions of 68,152,000 kg CO2e, and Scope 3 emissions of 737,234,000 kg CO2e.
Jubilant Life Sciences aims to achieve net-zero emissions by 2050 for both its Scope 1 and Scope 2 emissions, with this commitment starting from 2023. This data is not cascaded from a parent or related organization; it is specific to Jubilant Life Sciences, although performance data is sourced from "Jubilant Pharmova Limited".
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more